Erratum. Predicting 10-Year Risk of End-Organ Complications of Type 2 Diabetes With and Without Metabolic Surgery: A Machine Learning Approach. Diabetes Care 2020;43:852–859

por Aminian, Ali, Zajichek, Alexander, Arterburn, David E., Wolski, Kathy E., Brethauer, Stacy A., Schauer, Philip R., Nissen, Steven E., Kattan, Michael W.
Publicado 2020

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

por Kumar, Anirudh, Patel, Divyang R., Brennan, Danielle M., Wolski, Kathy E., Lincoff, A. Michael, Ruotolo, Giacomo, McErlean, Ellen, Weerakkody, Govinda, Riesmeyer, Jeffrey S., Nicholls, Stephen J., Nissen, Steven E., Menon, Venu
Publicado 2019

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy

por Menon, Venu, Kumar, Anirudh, Patel, Divyang R., John, Julie St., Wolski, Kathy E., McErlean, Ellen, Riesmeyer, Jeffrey S., Weerakkody, Govinda, Ruotolo, Giacomo, Cremer, Paul C., Nicholls, Stephen J., Lincoff, A. Michael, Nissen, Steven E.
Publicado 2019

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

por Menon, Venu, Kumar, Anirudh, Patel, Divyang R, St John, Julie, Riesmeyer, Jeffrey, Weerakkody, Govinda, Ruotolo, Giacomo, Wolski, Kathy E, McErlean, Ellen, Cremer, Paul C, Nicholls, Stephen J, Lincoff, A Michael, Nissen, Steven E
Publicado 2020